BioMarin Pharma (BMRN) Misses Q4 EPS by 31c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Why has the market become so unforgiving of AI earnings?
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.46, $0.31 worse than the analyst estimate of $0.77. Revenue for the quarter came in at $875 million versus the consensus estimate of $829.31 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.95-$5.15, versus the consensus of $5.33. BioMarin Pharma sees FY2026 revenue of $3.325-3.425 billion, versus the consensus of $3.378 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Alamo Group (ALG) Misses Q3 EPS by 58c
- Metallus Inc. (MTUS) Tops Q3 EPS by 5c, Misses on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
